Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

518
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
518
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.4K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

355
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
355
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

330
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
330
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

579
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
579
Anatomy of the Heart01:27

Anatomy of the Heart

119.7K
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
119.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autograft versus Allograft in Indirect Corneal Neurotization: A Systematic Review.

American journal of ophthalmology·2026
Same author

High reproducibility of lipid core burden measurements with near-infrared spectroscopy and intravascular ultrasound imaging catheter.

International journal of cardiology. Heart & vasculature·2026
Same author

<i>Chlorella vulgaris</i> improves fertility in malnourished male rats by regulating the oxidative state, spermatogenesis, and inflammatory cytokines.

Open veterinary journal·2026
Same author

Semiology of functional/dissociative seizures in idiopathic generalized epilepsy: An inpatient video-electroencephalographic study.

Epilepsia·2026
Same author

Quercetin and low-dose gamma irradiation modulate oxidative stress, inflammation, autophagy, and apoptosis in DEN-induced hepatocarcinogenesis.

Genes & nutrition·2026
Same author

Characterization of Novel Partially Bio-Based, Waste-Derived Composites for Thermal and Acoustic Performance in Buildings.

Polymers·2026

Related Experiment Video

Updated: Jan 30, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.0K

Erectile Dysfunction and Ischaemic Heart Disease.

Abdalla Ibrahim1, Mohamed Ali2, Thomas J Kiernan1

  • 1Cardiology Department, University Hospital Limerick Limerick, Ireland.

European Cardiology
|January 31, 2019
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) is a common vascular disorder, often linked to atherosclerosis risk factors. Managing these factors and using phosphodiesterase type 5 inhibitors can effectively treat ED, improving patient quality of life.

Keywords:
Atherosclerosisendothelial dysfunctionerectile dysfunctionischaemic heart diseasephosphodiesterase inhibitors

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.1K

Related Experiment Videos

Last Updated: Jan 30, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.0K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.1K

Area of Science:

  • Urology
  • Cardiology
  • Vascular Medicine

Background:

  • Erectile dysfunction (ED) significantly impacts quality of life, particularly in men over 60.
  • ED is increasingly recognized as a vascular disorder, with endothelial dysfunction as a key pathological process.
  • Common cardiovascular risk factors like diabetes, hypertension, and hyperlipidemia are prevalent in ED patients.

Purpose of the Study:

  • To highlight the vascular basis of erectile dysfunction.
  • To emphasize the role of managing cardiovascular risk factors in ED prevention.
  • To review the efficacy of phosphodiesterase type 5 inhibitors in treating ED.

Main Methods:

  • Review of current evidence linking ED to vascular health and atherosclerosis.
  • Analysis of the role of endothelial dysfunction in ED pathogenesis.
  • Evaluation of treatment strategies, including risk factor management and pharmacotherapy.

Main Results:

  • ED is predominantly a vascular issue, often stemming from endothelial dysfunction.
  • Cardiovascular risk factors are strongly associated with ED prevalence.
  • Phosphodiesterase type 5 inhibitors are effective and safe for ED treatment, even in patients with heart conditions.

Conclusions:

  • Management of cardiovascular risk factors is crucial for preventing and treating ED.
  • Phosphodiesterase type 5 inhibitors offer a valuable therapeutic option for ED.
  • Addressing the vascular underpinnings of ED improves patient outcomes and quality of life.